At the closing of the Business Combination (the “Closing”), and subject to the terms and conditions of the Business Combination Agreement, (i) each outstanding share of Legacy Amprius common stock was canceled and converted into the right to receive the number of shares of the Issuer’s Common Stock equal to such number of shares multiplied by approximately 1.45590 (the “Exchange Ratio”) and (ii) each option to purchase shares of Legacy Amprius common stock (a “Legacy Amprius Option”) whether vested or unvested, converted into an option to purchase a number of shares of Common Stock equal to the product (rounded down to the nearest whole number) of (x) the number of shares of Legacy Amprius common stock subject to such Legacy Amprius Option immediately prior to the Closing and (y) the Exchange Ratio, at an exercise price per share (rounded up to the nearest whole cent) equal to (A) the exercise price per share of such Legacy Amprius Option immediately prior to the Closing divided by (B) the Exchange Ratio. All of the shares of Common Stock reported herein as beneficially owned by the Reporting Person were acquired in connection with the Closing.
On the Closing Date, a number of investors (the “PIPE Investors”) purchased from the Issuer an aggregate of 2,052,500 PIPE Units at a price of $10.00 per PIPE Unit (such transaction, the “PIPE”), pursuant to separate subscription agreements (each, a “Subscription Agreement”) entered into with the PIPE Investors. Each “PIPE Unit” consists of (i) one share of Common Stock and (ii) one warrant (each, a “PIPE Warrant”) to purchase one share of Common Stock at an exercise price of $12.50. The Dixon Revocable Trust, of which Mr. Dixon is co-trustee, the Yi Cui and Meng Sui Family Trust, of which Dr. Cui is co-trustee, Dr. Chu, and entities affiliated with VantagePoint Capital Partners purchased 100,000 PIPE Units, 25,000 PIPE Units, 2,500 PIPE Units and 200,000 PIPE Units, respectively, in the PIPE.
The information set forth in or incorporated by reference into Items 4, 5 and 6 of this Schedule 13D is hereby incorporated by reference in its entirety into this Item 3.
Item 4. Purpose of Transaction
The Reporting Person was the majority stockholder of Legacy Amprius. As a result of the Business Combination, which was effected for the purpose of providing funding to the Issuer, the Reporting Person became the majority stockholder of the Issuer. In such capacity, the Reporting Person may influence the corporate activities of the Issuer, including activities that may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.
Certain of the Related Persons serve as executive officers of the Issuer and/or as a member of the Issuer’s board of directors and, in such capacities, may influence the corporate activities of the Issuer, including activities that may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.
From time to time, the Related Persons who currently serve as officers and/or directors of the Issuer may also acquire beneficial ownership of additional shares of Common Stock or other securities of the Issuer as compensation, by purchase or otherwise, including (a) pursuant to the exercise of any outstanding stock options currently owned by the Related Persons or (b) upon receipt from the Issuer of future compensatory equity incentive awards for which such Related Person qualifies, including, but not limited to, awards of Common Stock, options to purchase shares of Common Stock, and restricted stock units for Common Stock. In addition, from time to time, the Related Persons may determine to dispose of all or a portion of the shares of Common Stock that are beneficially owned by the Related Persons and over which the Related Persons have investment power.
The Reporting Person is currently evaluating its options to facilitate its stockholders holding the Issuer’s Common Stock directly rather than holding it indirectly through the Reporting Person. Among the options that the Reporting Person is considering is a possible transaction whereby the Reporting Person would be acquired by or merge with a wholly owned subsidiary of the Issuer, whereby the Reporting Person’s stockholder would receive Common Stock in exchange for their interests in the Reporting Person. The terms of any such transaction would be subject to negotiation and approval by the Issuer’s board of directors. The Reporting Person may also decide to dividend or otherwise transfer the securities it owns in the Issuer to its stockholders, dispose of all or part of its investments in securities of the Issuer and/or enter into derivative transactions with institutional counterparties with respect to the Issuer’s securities, in each case subject to applicable securities laws, the lock-up restrictions set forth in the Issuer’s bylaws (the “Bylaws”), as described in Item 6 of this Schedule 13D, and any then-applicable policies of the Issuer.